On this day, the Ministry of Food and Drug Safety granted emergency approval to LaGevrio for mild to moderate adult COVID-19 patients who are at high risk of developing severe COVID-19 due to age, underlying disease, etc. According to data submitted by the office of Rep. Kim Seon-min of the Korea Reform Party on the 20th from the Korea Disease Control and Prevention Agency, the number of coronavirus treatments (Paxrovid, Lagebrio) introduced in the first and second quarters of this year was for 179,000 people. Paxrovid and Lagebrio as oral medications and Vechloriju as injections have been approved or approved for emergency use.
155 Dark Humor Jokes That Are Twisted, Morbid and Funny
According to the Korea Disease Control and Prevention Agency, the supply of Paxrovid, Lagebrio, and Veklury (injections) over the past three months was 1,812 units in May, 737 units in June, and 76,043 units in July. (Seoul = News 1) Reporter Park Jeong-ho = With the number of COVID-19 patients increasing in surrounding countries such as Hong Kong, Taiwan, and Singapore, on the afternoon of the 23rd, at Jongno Open Pharmacy, a pharmacy designated for COVID-19 treatment, in Jongno-gu, Seoul. Several domestic and foreign studies on the effects of Lagebrio show diverse results, but many studies suggest that the effects are more evident in the elderly aged 70 or older.
'Lagevrio' has been confirmed to have a preventive effect on COVID-19 hospitalization and mortality rates in the elderly in many overseas studies, including in the United States, Australia, and Hong Kong.
It replaces the RNA used in the replication process of the COVID-19 virus and prevents the virus from replicating. The supply volume has already increased significantly since July. Distribution of 'Therapeutic Use Guide' to medical institutions and medication guide to patients. The government's newly introduced edible new coronavirus infection (COVID-19) treatment, Lagebrio Capsule (ingredient molnupiravir), is safe. It can be used for adult patients with mild to moderate novel coronavirus infection (COVID-19) who are at high risk of progressing to severe disease.
Spokesperson Jang also said that there are a total of three treatments available in Korea regarding the shortage of treatments.
